Thursday, August 6, 2026 Login
Breaking
Scientists to study Sun’s mysteries during total eclipse Centre to launch Sampoorn Gobardhan Scheme on World Biofuel Day to boost CBG production North Korea’s Missiles Are Moving West — 120 of Them May Head Toward Ukraine Amid Kyiv’s Plea For Help Is Zendaya pregnant with her first child with Tom Holland? Truth behind viral baby bump photo revealed | Your Request Originates from an Undeclared Automated Tool
Business

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo – Reuters

By cpstestersofficial@gmail.com · August 6, 2026 · 1 min read

  1. Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo  Reuters
  2. Lilly’s Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk  ET Pharma
  3. GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk – National  Global News
  4. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress  Eli Lilly and Company
  5. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge  CNBC

Source link

Facebook X / Twitter WhatsApp

Related Stories

Leave a Comment

Your email address will not be published. Required fields are marked *